Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Respiratory Biologics Market Size Changed, over the years?

Recent years have seen a swift expansion in the size of the respiratory biologics market. The forecast indicates a growth from $6.38 billion in 2024 to $7.47 billion in 2025, displaying a compound annual growth rate (CAGR) of 17.0%. The burgeoning growth observed in the past can be associated with factors such as the upsurge in respiratory diseases, a rise in the acceptance of personalized medicine, increased spending on healthcare worldwide, improved awareness and diagnosis of respiratory conditions, coupled with a growing older population suffering from respiratory disorders.

How Much Will the Respiratory Biologics Market Be Worth in 2029?

It is projected that the market size for respiratory biologics will experience fast-paced growth in the coming years, escalating to $13.84 billion by 2029, with a substantive compound annual growth rate (CAGR) of 16.7%. Several factors are responsible for this growth during the forecast period, including the increasing prevalence of ailments such as asthma and COPD, augmented use of biologic therapies, increased spending on R&D endeavors, heightened demand for non-invasive methods of drug delivery, and broader reimbursement policies. Key factors expected to shape the market in this forecast period include the application of monoclonal antibodies in treating respiratory diseases, breakthroughs in the formulation and delivery of biologic drugs, regulatory approvals, strategic partnerships and acquisitions among leading players, and the incorporation of artificial intelligence in the discovery and development of new drugs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Which is the Largest Company in the Respiratory Biologics Market?

Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

What Are the Main Market Drivers in the Respiratory Biologics Industry?

The growth of the respiratory biologics market is being accelerated by the uptick in air pollution. Air pollution, which encompasses the introduction of damaging substances like gases, particulate matter, and biological molecules into the Earth’s atmosphere, poses significant threats to both human health and the environment. Factors such as growing industrialization and urbanization are escalating air pollution levels as they trigger an increase in pollutant emissions from factories, vehicles, and construction activities. To mitigate the detrimental health implications of air pollution, respiratory biologics offers targeted treatments that alleviate inflammation and enhance lung functionality in individuals exposed to airborne contaminants. For example, the Environmental Protection Agency, a US government body, reported in January 2025 that the United States had discharged over 66 million tons of pollutants into the atmosphere in 2023. Furthermore, the United Nations Environment Programme, an environmental authority based in Kenya, stated in September 2022 that due to air pollution, 7 million premature deaths occur annually, and 99% of the global population inhales unclean air. Consequently, the escalation in air pollution is catalyzing the expansion of the respiratory biologics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

How Is the Respiratory Biologics Market Segments Structured?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcuteneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegment:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

What Strategic Trends Are Transforming the Respiratory Biologics Market?

Leading firms in the respiratory biologics market are prioritizing the development of novel biologic therapies, such as targeted immune therapies for chronic respiratory ailments, in order to deliver more precise treatments that alleviate inflammation and enhance lung functionality. These targeted immune therapies aim to manage the body’s immune response so as to decrease swelling and alleviate breathing issues linked to long-term lung diseases. To illustrate, Sanofi S.A., a pharmaceutical company based in France, made an announcement in September 2024 that Dupixent (dupilumab) had received approval from the US Food and Drug Administration (FDA) for use as an adjunct maintenance therapy in adults suffering from inadequately managed chronic obstructive pulmonary disease (COPD) exhibiting an eosinophilic phenotype. This authorization symbolizes a significant breakthrough, with Dupixent being the first biologic drug to get approval in the US for the treatment of this particular subset of COPD patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

Which Global Regions Offer the Highest Growth in the Respiratory Biologics Market?

North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23497

This Report Delivers Insight On:

1. How big is the respiratory biologics market, and how is it changing globally?

2. Who are the major companies in the respiratory biologics market, and how are they performing?

3. What are the key opportunities and risks in the respiratory biologics market right now?

4. Which products or customer segments are growing the most in the respiratory biologics market?

5. What factors are helping or slowing down the growth of the respiratory biologics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model